High dose melphalan and ABMT with or without abdominal radiotherapy as consolidation treatment for ovarian carcinoma in complete remission or with microscopic residual disease.
We initiated in February 1982 a pilot study of high dose melphalan (HDM) and ABMT as consolidation treatment for ovarian carcinoma. Eleven patients entered into this study; 6 patients received HDM and ABMT (group 1), 5 patients received HDM in combination with flash abdominal radiotherapy followed by ABMT (group 2). Two of 6 group 1 patients and 3 of 5 group 2 patients are still alive with NED more than 3 years after ABMT (58+, 72+, 37+, 39+, 43+) and are hopefully cured. Main toxicity was haematological, we have not observed any death related to therapy. HDM and ABMT compared favorably with other consolidation treatments (abdominopelvic radiotherapy or IP chemotherapy) and merits a larger evaluation.
Dufour
P
P
Dept Onco-Hematology, CHU Hautepierre, Strasbourg.
Bergerat
J P
JP
Liu
K L
KL
Bohbot
A
A
Maloisel
F
F
Duclos
B
B
Herbrecht
R
R
Faradji
A
A
Jung
J M
JM
Oberling
F
F
D000008:Abdominal Neoplasms / Q000532:radiotherapy / Q000556:secondary; D000328:Adult; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000601:surgery; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D010052:Ovariectomy; D011379:Prognosis; D012074:Remission Induction; D014182:Transplantation, Autologous
D008558:Melphalan